Kamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 Million

Wall Street brokerages expect Kamada Ltd (NASDAQ:KMDA) to announce sales of $24.89 million for the current quarter, according to Zacks. Two analysts have provided estimates for Kamada’s earnings, with the highest sales estimate coming in at $28.17 million and the lowest estimate coming in at $21.60 million. Kamada reported sales of $11.65 million during the same quarter last year, which would suggest a positive year over year growth rate of 113.6%. The business is scheduled to report its next earnings results on Tuesday, May 15th.

On average, analysts expect that Kamada will report full year sales of $24.89 million for the current fiscal year, with estimates ranging from $117.50 million to $129.28 million. For the next financial year, analysts expect that the firm will report sales of $162.79 million per share, with estimates ranging from $139.80 million to $185.77 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Kamada.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.10. Kamada had a return on equity of 9.06% and a net margin of 6.71%. The firm had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million.

A number of research analysts have recently commented on the company. ValuEngine raised Kamada from a “sell” rating to a “hold” rating in a research report on Thursday, February 8th. Chardan Capital assumed coverage on Kamada in a research report on Friday, February 2nd. They set a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research cut Kamada from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 16th. HC Wainwright reaffirmed a “buy” rating on shares of Kamada in a research report on Thursday, February 8th. Finally, TheStreet raised Kamada from a “c” rating to a “b” rating in a research report on Friday, February 9th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $7.00.

Kamada (NASDAQ:KMDA) opened at $5.20 on Thursday. Kamada has a 1 year low of $3.75 and a 1 year high of $8.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.30. The company has a market capitalization of $207.35, a price-to-earnings ratio of 30.59 and a beta of 1.14.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in Kamada during the 3rd quarter worth about $112,000. Worth Venture Partners LLC purchased a new stake in Kamada during the 3rd quarter worth about $246,000. ARK Investment Management LLC purchased a new stake in Kamada during the 4th quarter worth about $251,000. Navellier & Associates Inc purchased a new stake in Kamada during the 2nd quarter worth about $303,000. Finally, Analyst IMS Investment Management Services Ltd. lifted its holdings in Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 50,000 shares in the last quarter. 6.26% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Kamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 Million” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/15/kamada-ltd-kmda-expected-to-post-quarterly-sales-of-24-89-million.html.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply